Arrowhead Pharmaceuticals, Inc. develops therapies using its RNA interference (RNAi) technology to target genes associated with diseases. The company focuses on creating drug candidates for various conditions, with its TRiM™ platform designed to silence disease-causing genes. Arrowhead operates in the biopharmaceutical sector, conducting clinical trials for its products, including plozasiran (ARO-APOC3), aimed at treating severe hypertriglyceridemia. Its customer base includes healthcare providers and patients in need of novel therapeutic solutions.
